NYSE:AMPE Ampio Pharmaceuticals (AMPE) Stock Forecast, Price & News $3.73 -0.22 (-5.57%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$3.62▼$4.0550-Day Range$0.26▼$5.0852-Week Range$3.35▼$21.00Volume34,257 shsAverage Volume20,028 shsMarket Capitalization$2.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media About Ampio Pharmaceuticals (NYSE:AMPE) StockAmpio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis-related pain. It focuses on the preclinical development of AR-300, a novel proprietary, small molecule formulation for the treatment of osteoarthritis of the knee. The company is headquartered in Englewood, Colorado.Read More AMPE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMPE Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comAmpio Pharmaceuticals to Present at the Emerging Growth ConferenceSeptember 25, 2023 | americanbankingnews.comAmpio Pharmaceuticals (NYSE:AMPE) Research Coverage Started at StockNews.comSeptember 26, 2023 | Altimetry (Ad)Fraud Expert: Dump these three popular stocksA major (and legal) market manipulation scheme is about to play out. It could cost you a fortune – or double your money. You choose. Find out what he knows, here.September 17, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Ampio Pharmaceuticals (NYSE:AMPE)September 7, 2023 | thestreet.comAmpio Pharmaceuticals (AMPE) Stock Tanks Today after Treatment Fails To Reach Primary EndpointAugust 31, 2023 | seekingalpha.comAmpio Pharmaceuticals announces 20-to-1 reverse stock splitAugust 31, 2023 | markets.businessinsider.comAmpio Pharmaceuticals Board Approves Reverse Stock Split - Quick FactsAugust 31, 2023 | finance.yahoo.comAmpio Pharmaceuticals Announces Reverse Stock SplitSeptember 26, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.August 3, 2023 | benzinga.comThinking about buying stock in Wavedancer, Urogen Pharma, Ampio Pharmaceuticals, Innoviz Technologies, or Rigetti Computing?June 22, 2023 | msn.com3 Biotech Stocks to Buy With Explosive Upside PotentialJune 3, 2023 | finance.yahoo.comAMPE - Ampio Pharmaceuticals, Inc.May 26, 2023 | finance.yahoo.comAmpio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common StockApril 18, 2023 | seekingalpha.comAmpio stock jumps ~20% after CEO letter on drug program, reorganizationApril 3, 2023 | thestreet.comAmpio Too Busy to Tell Investors Results of Eye Drug StudyFebruary 9, 2023 | thestreet.comWhy Ampio Pharmaceuticals (AMPE) Stock Is Plummeting TodayFebruary 7, 2023 | wsj.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Ampio Pharmaceuticals, Inc.December 27, 2022 | finance.yahoo.comAmpio Pharmaceuticals Regains Compliance with NYSE American Continued Listing StandardsNovember 17, 2022 | finance.yahoo.comAmpio Pharmaceuticals Announces NYSE American Removal of Trading SuspensionNovember 8, 2022 | finance.yahoo.comAmpio Pharmaceuticals Announces Fifteen-to-One Reverse Stock SplitOctober 16, 2022 | stockhouse.comMONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmOctober 16, 2022 | prnewswire.comAMPE DEADLINE TOMORROW: ROSEN, skilled investor counsel, Encourages Ampio Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important October 17 Deadline in Securities Class Action - AMPEOctober 12, 2022 | benzinga.comMONDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmOctober 7, 2022 | prnewswire.comROSEN, LEADING INVESTOR COUNSEL, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMPEOctober 4, 2022 | markets.businessinsider.comAmpio Pharmaceuticals Announces NYSE American Has Commenced Delisting ProceedingsOctober 3, 2022 | benzinga.comNYSE American to Suspend Trading Immediately in Ampio Pharmaceuticals, Inc. (AMPE) and Commence Delisting ProceedingsSeptember 30, 2022 | benzinga.comCLASS ACTION UPDATE for AMPE, TWTR and CNTA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersSee More Headlines Receive AMPE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMPE Company Calendar Last Earnings8/08/2023Today9/26/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:AMPE CUSIPN/A CIK1411906 Webampiopharma.com Phone720-437-6500Fax720-437-6501Employees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($20.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-139.54% Return on Assets-106.90% Debt Debt-to-Equity RatioN/A Current Ratio3.67 Quick Ratio3.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$15.62 per share Price / Book0.24Miscellaneous Outstanding Shares760,000Free Float730,000Market Cap$2.87 million OptionableOptionable Beta1.78 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Michael A. Martino (Age 66)CEO & Director Comp: $548.14kDr. David Bar-Or M.D. (Age 74)Founder & Chairman of Scientific Advisory Board Comp: $145.6kMr. Daniel G. Stokely CPA (Age 59)CPA, CFO, Corp. Sec. & Treasurer Comp: $346.73kDr. Howard Levy M.B.B.Ch. (Age 69)M.M.M., Ph.D., Chief Medical Officer April RamirezClinical Trial Mang.Key CompetitorsPhio PharmaceuticalsNASDAQ:PHIOAdial PharmaceuticalsNASDAQ:ADIL180 Life SciencesNASDAQ:ATNFPetros PharmaceuticalsNASDAQ:PTPIAgile TherapeuticsNASDAQ:AGRXView All CompetitorsInsidersJ Kevin BuchiBought 1,250 shares on 6/8/2023Total: $7,500.00 ($6.00/share)Michael A MartinoBought 3,844 shares on 5/24/2023Total: $22,295.20 ($5.80/share)David R StevensBought 2,500 shares on 5/11/2023Total: $11,000.00 ($4.40/share)View All Insider Transactions AMPE Stock - Frequently Asked Questions How have AMPE shares performed in 2023? Ampio Pharmaceuticals' stock was trading at $4.5040 at the start of the year. Since then, AMPE stock has decreased by 16.3% and is now trading at $3.77. View the best growth stocks for 2023 here. Are investors shorting Ampio Pharmaceuticals? Ampio Pharmaceuticals saw a increase in short interest in August. As of August 15th, there was short interest totaling 416,200 shares, an increase of 51.7% from the July 31st total of 274,300 shares. Based on an average daily trading volume, of 439,300 shares, the short-interest ratio is currently 0.9 days. Approximately 3.1% of the shares of the stock are short sold. View Ampio Pharmaceuticals' Short Interest. When is Ampio Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our AMPE earnings forecast. How were Ampio Pharmaceuticals' earnings last quarter? Ampio Pharmaceuticals, Inc. (NYSE:AMPE) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($1.80) earnings per share (EPS) for the quarter. When did Ampio Pharmaceuticals' stock split? Shares of Ampio Pharmaceuticals reverse split before market open on Tuesday, September 12th 2023. The 1-20 reverse split was announced on Thursday, August 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Ampio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ampio Pharmaceuticals investors own include Tesla (TSLA), Agenus (AGEN) and American Airlines Group (AAL). What is Ampio Pharmaceuticals' stock symbol? Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMPE." How do I buy shares of Ampio Pharmaceuticals? Shares of AMPE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ampio Pharmaceuticals' stock price today? One share of AMPE stock can currently be purchased for approximately $3.77. How much money does Ampio Pharmaceuticals make? Ampio Pharmaceuticals (NYSE:AMPE) has a market capitalization of $2.87 million. The company earns $-16,340,000.00 in net income (profit) each year or ($20.60) on an earnings per share basis. How can I contact Ampio Pharmaceuticals? Ampio Pharmaceuticals' mailing address is 373 Inverness Parkway, Suite 200, Englewood, CO 80112, United States. The official website for the company is ampiopharma.com. The company can be reached via phone at 720-437-6500, via email at info@ampiopharma.com, or via fax at 720-437-6501. This page (NYSE:AMPE) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.